How a tetravalent, tri-specific antibody aims to restore the blood–retinal barrier without directly inhibiting VEGF
Want the news story behind this science? Read my analysis of Merck’s Remigromig Meets the Phase 2b/3 BRUNELLO Endpoint in Diabetic Macular Edema.
Science at a Glance
| Category | Details |
|---|---|
| Candidate | Remigromig |
| Development code | MK-3000; formerly EYE103 and Restoret |
| Company | Merck, through EyeBio |
| Modality | Tetravalent, tri-specific agonist antibody |
| Targets | FZD4 and LRP5 |
| Pathway | Canonical Wnt/β-catenin signaling |
| Administration | Intravitreal injection |
| Lead indication | Diabetic macular edema |
Remigromig is designed to activate FZD4–LRP5 signaling in retinal endothelial cells. Unlike anti-VEGF drugs, it does not directly neutralize VEGF. Its proposed function is to restore the endothelial program that maintains the blood–retinal barrier.
Merck describes remigromig as an investigational, potentially first-in-class Wnt-pathway agonist currently in pivotal Phase 2b/3 development. (Merck remigromig overview)
How the Normal Blood–Retinal Barrier Works
Under normal conditions, Norrin activates a retinal endothelial receptor complex containing FZD4, LRP5 and TSPAN12.
This receptor complex recruits Dishevelled and suppresses the β-catenin destruction machinery. Stabilized β-catenin enters the nucleus, where it interacts with TCF/LEF transcription factors and supports genes required for endothelial barrier function.
Two important downstream proteins are:
- CLDN5, which strengthens tight junctions and limits leakage between endothelial cells
- MFSD2A, which suppresses vesicular transport through endothelial cells
Loss of Norrin–FZD4 signaling reduces these barrier-associated genes, while FZD4–LRP5 agonism can restore much of the affected endothelial program. (FZD4–LRP5 barrier study)
The figure below summarizes normal blood–retinal barrier maintenance, DME-associated barrier dysfunction and the proposed effect of remigromig.
[Figure 1: Remigromig mechanism in diabetic macular edema]
How Remigromig Restores Barrier Signaling
In diabetic macular edema, hyperglycemia, inflammation and VEGF-associated vascular stress weaken retinal endothelial integrity. Tight junctions become disrupted, transcytosis increases and fluid accumulates in the macula.
Remigromig is designed to bring FZD4 and LRP5 into close proximity and reactivate β-catenin-dependent barrier signaling.
The antibody is described as tetravalent because it has four binding sites and tri-specific because those sites recognize three molecular epitopes—not three different proteins.
The published F4L5.13 prototype underlying this approach contains two equivalent FZD4-binding paratopes and two distinct LRP5-binding paratopes. This structure promotes receptor clustering and initiates Wnt/β-catenin signaling. (EMBO Molecular Medicine)
Remigromig → FZD4–LRP5 clustering → β-catenin stabilization → CLDN5 and MFSD2A support → stronger blood–retinal barrier
Wnt/β-catenin signaling can directly increase MFSD2A and suppress caveolin-1-positive endothelial transcytosis, providing a molecular route for reducing leakage through retinal endothelial cells. (Science Advances)
Remigromig vs. Anti-VEGF Therapy
| Approach | Primary action |
|---|---|
| Anti-VEGF therapy | Blocks VEGF-mediated permeability and angiogenic signaling |
| Remigromig | Activates FZD4–LRP5 signaling to reinforce the endothelial barrier |
Anti-VEGF therapy reduces a major signal that drives vascular leakage. Remigromig instead aims to strengthen the barrier itself.
This mechanistic difference does not establish superior efficacy, durability or disease modification. Those questions require complete clinical efficacy and safety data.
BP Science View
Remigromig represents a shift from blocking a permeability driver to activating an endogenous barrier-restoration pathway.
Its molecular rationale is clear: FZD4–LRP5 clustering stabilizes β-catenin, supporting tight-junction integrity and suppressing endothelial transcytosis through proteins including CLDN5 and MFSD2A.
The key question is whether this distinct mechanism can translate into sustained control of retinal leakage with an acceptable safety profile.
About BP Science
BP Science explains the molecular mechanisms behind emerging biotechnology and pharmaceutical innovation.
This article is for scientific and educational purposes only and does not constitute medical or investment advice.
Leave a Reply